A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria: 1. Signed Written Informed Consent 2. Adult patients (≥18 years old) 3. ECOG Performance Status score of 0, 1, or 2. 4. Participant has documented diagnosis of multiple myeloma (MM) and measurable disease, defined as any of the following: 1. M-protein ≥ 0.5 g/dL by serum protein electrophoresis (sPEP), or 2. M-protein ≥ 200 mg/24-hour urine collection by urine protein electrophoresis (uPEP) or, 3. For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels \> 100 mg/L (10 mg/dL) involved light chain and an abnormal κ/λ FLC ratio. 5. Participant has received one or two prior line of anti-myeloma therapy. Note: One line can contain several phases (eg, induction, \[with or without\] hematopoietic stem cell transplant, (with or without) consolidation, and/or \[with or without\] maintenance therapy). 6. Participant must have received prior treatment with lenalidomide and an anti-CD38 monoclonal antibody. 7. Participant ach…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source